Is propranolol appropriate for treating hyper‑active ICU delirium, and what are the indications, contraindications, dosing, and monitoring recommendations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Propranolol is NOT Recommended for ICU Delirium

Propranolol should not be used as a treatment for hyperactive ICU delirium. There is no guideline support or high-quality evidence for this indication, and established alternatives with proven efficacy exist.

Why Propranolol is Inappropriate

Lack of Evidence-Based Support

The 2013 and 2025 SCCM Clinical Practice Guidelines for ICU delirium management make no mention of propranolol as a treatment option 1, 2. The guidelines specifically address:

  • Antipsychotics (haloperidol, atypical antipsychotics) - though evidence shows they don't reduce delirium duration 1, 3
  • Dexmedetomidine - conditionally recommended over benzodiazepines for sedation in delirious patients (2B recommendation) 1, 2
  • Non-pharmacologic interventions - early mobilization (1B recommendation) 1

Limited and Low-Quality Data

Only one small retrospective case series (n=27 episodes) examined propranolol's sedative effects in ICU patients 4. While it showed reduced sedative/analgesic requirements, this was:

  • Retrospective and uncontrolled
  • Not designed to assess delirium outcomes
  • Confounded by concurrent clinical changes
  • Never replicated or validated

Safety Concerns in Critical Illness

Propranolol carries significant contraindications highly relevant to ICU patients 5:

  • Cardiogenic shock (absolute contraindication)
  • Bradycardia and heart blocks (absolute contraindication)
  • Bronchospasm risk (contraindicated in asthma)
  • Hypotension - can worsen hemodynamic instability
  • Masks hypoglycemia - dangerous in critically ill patients
  • Drug interactions - extensive CYP450 interactions with common ICU medications 5

What TO Use Instead

For Hyperactive Delirium Requiring Sedation

Use dexmedetomidine rather than benzodiazepines when sedation is needed in delirious ICU patients (unless delirium is from alcohol/benzodiazepine withdrawal) 1, 2.

Recent high-quality evidence strongly supports this:

  • The 4D trial (2025) showed dexmedetomidine significantly reduced agitation duration in non-intubated hyperactive delirious patients (median 1 vs 2 hours, p=0.001) 6
  • The BaProDex trial (2025) found shorter delirium duration with overnight dexmedetomidine vs propofol (31 vs 66 hours in per-protocol analysis, HR 2.95, p=0.012) 7
  • The 2025 SCCM update issued a conditional recommendation for dexmedetomidine over propofol for sedation 2

Dosing approach for dexmedetomidine:

  • Start 0.2-0.7 mcg/kg/h IV infusion (no loading dose needed for delirium)
  • Titrate to light sedation (RASS 0 to -2)
  • Monitor for bradycardia and hypotension

Non-Pharmacologic Management (First-Line)

Prioritize these evidence-based interventions 1:

  1. Early mobilization - strongest recommendation (1B) to reduce delirium incidence and duration
  2. Sleep optimization - control light/noise, cluster care activities, minimize nighttime stimulation (1C)
  3. Avoid benzodiazepines - they are a risk factor for delirium development 1
  4. Maintain light sedation - target RASS 0 to -1 when sedation needed (1B)
  5. Analgesia-first approach - treat pain before sedating (2B)

Antipsychotics: Limited Role

Do NOT use haloperidol or atypical antipsychotics prophylactically (2C recommendation) 1. For treatment:

  • No evidence haloperidol reduces delirium duration 1
  • The MIND-USA trial (2018) showed neither haloperidol nor ziprasidone improved delirium outcomes vs placebo 3
  • Withhold in patients with QTc prolongation or torsades risk (2C) 1

Clinical Algorithm for Hyperactive ICU Delirium

  1. Assess and treat reversible causes (hypoxia, infection, metabolic derangements, pain)
  2. Implement non-pharmacologic measures (mobilization, sleep hygiene, reorientation)
  3. If sedation required:
    • Use dexmedetomidine 0.2-0.7 mcg/kg/h
    • Avoid benzodiazepines (unless alcohol/benzodiazepine withdrawal)
    • Target light sedation (RASS 0 to -2)
  4. Monitor with validated tools (CAM-ICU or ICDSC) at least 3x daily 1
  5. Avoid propranolol - no evidence, significant safety concerns

Key Pitfalls to Avoid

  • Don't use beta-blockers for delirium - no evidence base and multiple contraindications in critical illness
  • Don't prophylax with antipsychotics - ineffective and potentially harmful 1
  • Don't use deep sedation - associated with worse outcomes; target light sedation 1
  • Don't forget non-pharmacologic interventions - these have the strongest evidence for prevention 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.